Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses

NCT07002034 is registered in ClinicalTrials.gov with Reunion Neuroscience Inc as lead sponsor.

NCT NCT07002034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07002034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Lead sponsor
Reunion Neuroscience Inc
Phase
Phase 2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

adjustment disorder